HCW Biologics Inc. (HCWB) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Miramar, FL, アメリカ. 現CEOは Hing C. Wong.
HCWB を有する IPO日 2021-07-20, 36 名の正社員, に上場 NASDAQ Global Market, 時価総額 $721.7K.
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
